CVasThera was founded in 2016 by highly experienced pharmaceutical industry professionals, with a world-class track record of CV drug discovery, drug development, clinical trials, and company management. We are experienced professionals in pre-clinical and clinical development who know that there is a better way to develop drugs.
Patent protection for pharmaceutical products in the developing world can help to encourage the development of new medicines for diseases that affect these countries, by providing protection for the investments that need to be made by the pharmaceutical companies. Pharmaceutical companies often maintain that patent protection for drugs ensures that they are able to invest billions of dollars into the development of new products, by making sure that they will be able to take advantage of the sales. Based on long experiences , CVasThera was dedicated to assure the innovation of new proposal patents.
New identified compound or target molecule is of high interest, but it is often just a first step in a long process that will determine the potential of this compound or a related congener to be developed into an authority-approved drug. Many of the early clincial trials are performed with a drug known to work safely in one indication, to support a new label expansion but integrative physiology and/or pharmacology is oftenly bypassed. Integrate biological, chemical and pharmacological data to help drive innovation and support earlier decision-making when developing new hypotheses around targets, drugs, and how to translate animal models into humans is our area of expertise.
While basic discovery research is funded primarily by government and by philanthropic organizations, early-stage development is funded mainly by pharmaceutical companies or venture capitalists. At CVasThera, we are dedicated to accelerating innovation and advancing science at early-stage development. That’s why we want to foster independent research by reducing financial hurdles for researchers.
Proof-Of-Concept (POC) is a pivotal milestone in the drug development process. In front of the failure number, the early development processes must be re-engineered to improve R&D productivity and shorten project timelines, whilst at the same time allowing a more flexible and interrogative investigation of a drug candidates unique potential. Based on long experiences , CVasThera was dedicated to evaluating integrated and adaptive clinical protocols combining healthy volunteer and POC investigations.
Patent protection for pharmaceutical products in the developing world can help to encourage the development of new medicines for diseases that affect these countries, by providing protection for the investments that need to be made by the pharmaceutical companies. Pharmaceutical companies often maintain that patent protection for drugs ensures that they are able to invest billions of dollars into the development of new products, by making sure that they will be able to take advantage of the sales. Based on long experiences , CVasThera was dedicated to assure the innovation of new proposal patents.
New identified compound or target molecule is of high interest, but it is often just a first step in a long process that will determine the potential of this compound or a related congener to be developed into an authority-approved drug. Many of the early clincial trials are performed with a drug known to work safely in one indication, to support a new label expansion but integrative physiology and/or pharmacology is oftenly bypassed. Integrate biological, chemical and pharmacological data to help drive innovation and support earlier decision-making when developing new hypotheses around targets, drugs, and how to translate animal models into humans is our area of expertise.
The expertise of CVasThera is engaged in promising projects.
Expertise and analyses for Boston Pharma’s project.
Expertise and CSO position for OP2 drugs project
Project leads by CvasThera, a new target to treat crisis, prevent relapses, and pain.
Together we go further faster. We value collaboration vs competition. We reach out to potential partners worldwide who share our values and commitment to global health.
CVasThera signs an agreement that provide expertise to Boston Pharma relating to BOS1728515 program in pre-clinical or clinical development for the treatment of postoperative atrial fibrillation...
CVasThera signs an agreement that provide, expertise to the OP2drugs relating to OP2113 program in pre-clinical development for the treatment of acute myocardial infarction...
The french ministry of Education, Research and Innovation has approved CVasThera for the CIR. With this agreement, CVasThera has been now recognized skillful for performing R&D projects in France for the three next years...
OP2 drugs appoints Bruno LE GRAND chief scientifical officer...
CVasThera has received a grant research from "Région Occitanie" to advance development of CVT12011965 a promising candidate for treatment of crohn disease (CD). The grant will support research studies carried out by INSERM Toulouse and for the develpment an innovative galenic form carried out by GALA castres.